All In Biotech

Drug Trial Radar · NCT01772004

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Last checked: Nov 20, 2026Latest source record: Dec 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

1,756

Actual

Start

Jan 31, 2013

Primary completion

Dec 16, 2019

Study completion Dec 16, 2019

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Jan 21, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, dose-escalation trial of avelumab \[antibody targeting programmed death ligand 1 (anti PD-L1)\] with consecutive parallel group expansion in participants with selected tumor indications. New recruitment is open for all active cohorts. Active cohorts: Escalation revised dosing regimen cohort. Closed cohorts: Non-small cell lung cancer (NSCLC, first line), NSCLC (post-platinum), metastatic breast cancer (MBC), colorectal cancer (CRC), urothelial carcinoma (secondary), mesothelioma, gastric/GEJ cancer (first line switch maintenance and second line), and ovarian cancer (secondary and platinum refractory + liposomal doxorubicin), renal cell carcinoma (second line) melanoma and head, neck squamous cell carcinoma (HNSCC), castrate-resistant prostate cancer (CRPC), adrenocortical carcinoma (ACC) urothelial carcinoma (efficacy), gastric/gastroesophageal junction (GEJ) cancer (third line), renal cell carcinoma (RCC, first line) and escalation phase .

Conditions

  • Solid Tumors

Interventions

  • AvelumabDrug

    Participants received intravenous infusion of Avelumab in dose escalation and expansion cohorts until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs)Time frame: Dose Escalation: Baseline up to Week 3
  2. Efficacy Expansion Cohort (Ovarian Cancer): Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), as Adjudicated by Independent Endpoint Review Committee (IERC)Time frame: Ovarian Cancer Efficacy Expansion: Baseline up to Day 620
  3. Efficacy Expansion Cohort(Urothelial Carcinoma): Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), as Adjudicated by Independent Endpoint Review Committee (IERC)Time frame: Urothelial Carcinoma Efficacy Expansion: Baseline up to Day 931
  4. Efficacy Expansion Cohort (GC/GEJC, Third Line): Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), as Adjudicated by Independent Endpoint Review Committee (IERC)Time frame: GC/GEJC, Third Line Efficacy Expansion: Baseline up to Day 871
  5. Efficacy Expansion Cohort (HNSCC): Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), as Adjudicated by Independent Endpoint Review Committee (IERC)Time frame: HNSCC Efficacy Expansion: Baseline up to Day 1072

Locations

74 sites in 9 countries. Site status is shown where the registry gives one.

  • Cancer Treatment Centers of America - Western Regional Medical Center

    Goodyear, Arizona

  • Scottsdale Healthcare Corporation

    Scottsdale, Arizona

  • Pinnacle Oncology Hematology

    Scottsdale, Arizona

  • Highlands Oncology Group

    Rogers, Arkansas

  • Pacific Cancer Medical Center, Inc.

    Anaheim, California

  • California Cancer Associates for Research & Excellence, Inc

    Encinitas, California

  • Healing Hands Oncology and Medical Care

    Inglewood, California

  • Scripps Health dba Scripps Clinical Research Services

    La Jolla, California

  • The Angeles Clinic and Research Institute - West LA

    Los Angeles, California

  • Cedars-Sinai Medical Center - Oncology

    Los Angeles, California

  • University of California Davis Health System

    Sacramento, California

  • Sharp Memorial Hospital

    San Diego, California

  • Georgetown University Medical Center- Research Parent

    Washington D.C., District of Columbia

  • Holy Cross Hospital

    Fort Lauderdale, Florida

  • University of Miami

    Miami, Florida

  • Hematology - Oncology Associates of Treasure Coast - Hematology-Oncology Associates of Treasure Coast

    Port Saint Lucie, Florida

  • Florida Cancer Specialists

    Sarasota, Florida

  • Northeast Georgia Cancer Care, LLC

    Athens, Georgia

  • Peachtree Hematology-Oncology Consultants, PC

    Atlanta, Georgia

  • Augusta University - formerly Georgia Regents University

    Augusta, Georgia

  • Northwest Georgia Oncology Centers PC

    Marietta, Georgia

  • University of Chicago Medical Center

    Chicago, Illinois

  • Horizon Oncology Research, INC

    Lafayette, Indiana

  • The Johns Hopkins Hospital

    Baltimore, Maryland

  • RCCA MD LLC - Bethesda

    Bethesda, Maryland

  • National Cancer Institute

    Bethesda, Maryland

  • Maryland Oncology Hematology, P.A.

    Rockville, Maryland

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Henry Ford Medical Center

    Detroit, Michigan

  • Michigan State University

    Lansing, Michigan

  • Virginia Piper Cancer Institute

    Minneapolis, Minnesota

  • Kansas City Research Institute, LLC - Phase I Unit

    Kansas City, Missouri

  • Washington University in St. Louis

    St Louis, Missouri

  • San Juan Oncology Associates

    Farmington, New Mexico

  • Columbia University College of Phys & Surgeons

    New York, New York

  • Montefiore Medical Center PRIME

    The Bronx, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center

    Huntersville, North Carolina

  • UC Health Clinical Trials Office

    Cincinnati, Ohio

  • University Hospitals Case Medical Center - Case Comprehensive Cancer Center

    Cleveland, Ohio

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.